PDIA4, a novel ER stress chaperone, modulates adiponectin expression and inflammation in adipose tissue

• Published in: BioFactors (Oxford) 2022-09, Vol.48 (5), p.1060-1075
• Main Authors: Su, Sheng‐Chiang, Chien, Chu‐Yen, Chen, Ying‐Chen, Chiang, Chi‐Fu, Lin, Fu‐Huang, Kuo, Feng‐Chih, Huang, Chia‐Luen, Li, Peng‐Fei, Liu, Jhih‐Syuan, Lu, Chieh‐Hua, Ho, Li‐Ju, Hsieh, Chang‐Hsun, Hung, Yi‐Jen, Shieh, Yi‐Shing, Lee, Chien‐Hsing
• Format: Article
• Language: English
• Subjects: adiponectin; adipose inflammation; ER stress; metformin; PDIA4
• ISSN: 0951-6433; 1872-8081
• DOI: 10.1002/biof.1872

Increasing evidence supporting a causal link between obesity and endoplasmic reticulum (ER) stress in adipose tissue is being reported. Protein disulfide isomerase 4 (PDIA4) is a novel ER chaperone involved in the pancreatic β‐cells pathogenesis in diabetes. However, the role of PDIA4 in obesity progression remains poorly understood. To assess the relationship between PDIA4, adiponectin, and metformin, we used the palmitate‐induced inflammation in hypertrophic adipocytes and the high‐fat diet‐induced obesity mouse model. Our results revealed that palmitate‐induced hypertrophic adipocytes exhibit obesity‐associated conditions such as increased lipid accumulation, inflammation, and reduced glucose uptake. Pharmacological and genetic inhibition of PDIA4 significantly reverses these obesity‐associated conditions in adipocytes. PDIA4 mechanistically promotes obesity progression via adiponectin downregulation. Furthermore, metformin modulates PDIA4 and adiponectin expression and improves obesity‐associated conditions in both in vitro adipocytes and in vivo mouse models. Serum PDIA4 concentrations are also associated with body mass index, adiponectin, triglycerides, and inflammatory cytokines in humans. This is the first study demonstrating that PDIA4 modulates adipocytes by downregulating adiponectin. Moreover, metformin may serve as a potential therapeutic for preventing obesity via PDIA4‐targeting.